Literature DB >> 9549248

A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia.

A Labelle, R de Beaurepaire, L J Boulay, D Naber, B D Jones, T R Barnes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9549248      PMCID： PMC1188906     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  6 in total

1.  A rating scale for extrapyramidal side effects.

Authors:  G M Simpson; J W Angus
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

2.  An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states.

Authors:  R de Beaurepaire; A Labelle; D Naber; B D Jones; T R Barnes
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

3.  Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients.

Authors:  P Karlsson; L Smith; L Farde; C Härnryd; G Sedvall; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

4.  Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia.

Authors:  J A Den Boer; H J van Megen; W W Fleischhacker; J W Louwerens; B R Slaap; H G Westenberg; G D Burrows; O N Srivastava
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 5.  Utilization of radioligands in schizophrenia research.

Authors:  G Sedvall; L Farde; H Hall; C Halldin; P Karlsson; A L Nordström; S Nyberg; S Pauli
Journal:  Clin Neurosci       Date:  1995

6.  In vivo binding of SCH 39166: a D-1 selective antagonist.

Authors:  R D McQuade; R A Duffy; V L Coffin; R E Chipkin; A Barnett
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030
  6 in total
  3 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.